Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Preclinical Models for In-Vivo CAR-T Cell Persistence and Exhaustion

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Preclinical Models for In-Vivo CAR-T Cell Persistence and Exhaustion

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in Preclinical Cellular Therapy.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

Executive Summary

Evaluating the long-term persistence and functional exhaustion of CAR-T cells is a primary objective for any preclinical program. Standard models can fail to recapitulate the complex interactions between the therapeutic cells, the tumor microenvironment, and the host immune system. Our approach outlines a tailored, data-driven strategy for selecting and executing in vivo studies that generate decision-quality data for Investigational Medicinal Product Dossier (IMPD) and Investigational New Drug (IND) submissions, aligning with harmonized international guidelines (ICH).

Frequently Asked Questions

How do you model CAR-T cell exhaustion in preclinical programs for next-generation therapies?

We utilize a multi-faceted approach that combines long-term in vivo studies in highly relevant animal models with deep immunological profiling. By monitoring key exhaustion markers (e.g., PD-1, TIM-3, LAG-3) on CAR-T cells recovered from tumor and lymphoid tissues over time, we can correlate phenotype with anti-tumor activity and persistence, providing data for minimizing clinical risk.

What are the key differences between syngeneic and humanized in vivo platforms for CAR-T evaluation?

Syngeneic platforms use immunocompetent hosts, which is ideal for studying interactions with a complete, functional immune system. Humanized platforms involve immunodeficient hosts engrafted with human immune cells and tumors, offering a system to assess human-specific CAR-T constructs directly. The choice depends on the specific scientific questions guiding the IND-enabling toxicology studies.

How do your preclinical models support IND and IMPD submissions for cell therapies in Germany and the EU?

Our preclinical strategies are designed from the outset to meet the rigorous standards of global regulatory bodies, including the Paul-Ehrlich-Institut and EMA. We generate comprehensive data packages covering efficacy, non-target tissue biodistribution, and potential toxicities, structured to facilitate a streamlined review process for multi-jurisdictional submissions.

Tailoring Preclinical Strategy for CAR-T Durability

A standardized preclinical testing template does not exist for somatic cell therapies. The central challenge lies in selecting an in vivo model that accurately predicts clinical outcomes related to cell persistence and the onset of T-cell exhaustion. The decision between using a platform with a fully intact immune system versus one designed to test human-specific constructs requires a deep understanding of the therapeutic’s mechanism of action and target indication.

Our approach is built on a foundation of scientific rationale, ensuring the selected model provides the most relevant data for your program. This includes evaluating:

  • Tumor growth kinetics and establishment.

  • CAR-T cell trafficking, infiltration, and expansion at the tumor site.

  • Longitudinal monitoring of anti-tumor efficacy.

  • Terminal analysis of immune cell populations in tissues.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Applying Immunological Principles to Cellular Therapy

Insights from adjacent fields, such as viral vector immunology, provide a valuable framework for understanding and mitigating challenges in CAR-T development. For instance, investigations into AAV-mediated immune responses have demonstrated that T-cell exhaustion can be a mechanism for inducing tolerance, a phenomenon that has direct parallels to the functional decline of CAR-T cells (PMID: 23778424).

The ability to identify and track specific T-cell epitopes was a key step in characterizing immune responses to AAV capsids (PMID: 19777488). We apply this same principle to CAR-T programs, developing phase-appropriate, GxP-compliant assays to precisely monitor the persistence and phenotype of the therapeutic cell population in biological samples.

Execution within a Global Regulatory Framework

For sponsors based in Germany and across the EU, preclinical data must support an IMPD submission that satisfies stringent European requirements. Our study directors possess the experience to design and execute programs that generate a cohesive data narrative, aligning with ICH guidelines to support parallel IND submissions to the FDA. This integrated approach is backed by a 100% successful IND rate since 2019, a track record established by our core scientific team prior to the formal launch of Franklin Biolabs in 2024.

Our work with partners like Moderna on RNA and LNP delivery systems has further refined our expertise in managing complex immunological endpoints for next-generation therapies. This positions us to de-risk your CAR-T program and accelerate timelines, typically moving candidates toward IND within 18-24 months. These programs are executed within our >100,000 sq ft of dedicated preclinical and bioanalytical facilities.

For more information on our comprehensive services, please see our main Cell and Gene Therapy CRO Services page.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities